01—Abstract
Summary
Summary of the 8-K filed September 3, 2025. Cited figures are marked; the original filing is the authoritative source.
Cencora, Inc. (COR) disclosed in this Form 8-K, filed September 3, 2025, that it has reached a proposed settlement of the stockholder derivative action Lebanon County Employees' Retirement Fund v.
Collis (C.A. No. 2021-1118-JTL) in Delaware's Court of Chancery. Under the Stipulation dated August 15, 2025, the Company's insurance carriers would pay $111.25 milliona into escrow, less any attorneys' fees and litigation expenses the Court awards to plaintiffs' counsel.
The proceeds would go to the Company, not to individual stockholders, and no proof-of-claim action is required from shareholders. The settlement is subject to Court approval, with a Settlement Hearing scheduled for November 13, 2025. The case alleges that the Board and certain officers breached fiduciary duties through oversight of controlled substance diversion controls, tied to the Company's opioid distribution.
The complaint sought damages the plaintiffs alleged cost the Company more than $7 billionb. The defendants deny all wrongdoing, and the Stipulation contains no admission of liability. The matter had been stayed since March 2024 while a Special Litigation Committee investigated the allegations.
The SLC reached an agreement in principle after a June 24, 2025 mediation before Judge Layn Phillips. For investors, the key takeaways are that the payment is funded by insurers rather than Company cash, that it is a relatively modest recovery relative to the alleged damages, and that the settlement resolves derivative claims against the individual defendants without any admission of fault.
Remaining risks include whether the Court approves the settlement, how much of the payment is reduced by fee awards, and the fact that the release does not cover direct securities claims by stockholders. The settlement does not appear to resolve the separate DOJ civil action filed in December 2022 against the Company under the Controlled Substances Act.
02—Key points
Key Highlights
- Proposed settlement of the opioid-related stockholder derivative action pays $111.25 million, funded by insurance carriers and payable to the Company after attorneys' fees and expenses are deducted.
- The settlement is subject to Delaware Court of Chancery approval; the Settlement Hearing is scheduled for November 13, 2025, with objections due October 29, 2025.
- No admission of liability: defendants expressly deny wrongdoing and the Stipulation states it is not evidence of any fault.
- Plaintiffs' complaint alleged the Company's losses from opioid distribution exceeded $7 billion, so the recovery is a small fraction of the alleged damages.
- Individual stockholders receive no direct payment and no proof of claim is required; the release does not cover direct claims, including federal securities law claims.
- Attorneys' fees and litigation expenses requested for plaintiffs' counsel are capped at 25% of the settlement fund and would be deducted before the Company receives funds.
- The settlement does not resolve the separate December 2022 DOJ civil action against the Company alleging Controlled Substances Act violations.
03—Questions
Frequently Asked Questions
How much will Cencora receive from this settlement?
Insurers would pay $111.25 million into escrow. After any Court-awarded attorneys' fees and litigation expenses (capped at 25% of the fund) and applicable taxes on interest, the net amount would be paid to the Company within ten business days after the settlement becomes effective.
Do I need to take any action as a shareholder?
No. The notice states there is no proof-of-claim form and stockholders are not required to act. Stockholders who wish to object must do so in writing by October 29, 2025, and must have held shares through the November 13, 2025 hearing.
Does the settlement mean Cencora admitted wrongdoing?
No. The Stipulation states it is not an admission of liability, and the defendants continue to deny all allegations of fault, breach of fiduciary duty, or wrongdoing.
What happens if the Court does not approve the settlement?
The settlement can be terminated by any party under specified conditions, including a final Court refusal to approve it. If terminated, the parties revert to their positions before the June 2025 term sheet and the escrowed funds would be returned to the individual defendants' insurers or designees.
Is this settlement the end of Cencora's opioid-related legal exposure?
No. The release covers only the derivative claims in this action and related Section 220 and derivative matters. It does not release direct stockholder claims, including federal securities claims, and does not address the DOJ civil action filed in December 2022 or the broader opioid-related obligations described in the filing.
04—Continue